Fig. 5 | Scientific Reports

Fig. 5

From: Development and validation of an Immune-related Gene-based model for predicting prognosis and immunotherapy outcomes in hepatocellular carcinoma patients

Fig. 5

Predictive value of the IRGPI for immunotherapy. (A) Distribution of IRGPI scores in the IMvigor210 cohort. A trend toward a decreased IRGPI in patients with complete or partial response (CR/PR) compared with those with progressive disease or stable disease (PD/SD) was observed. (B) OS was longer in patients with high IRGPI scores in the IMvigor210 cohort. (C) Immunohistochemistry results for PD-L1 (SP142, 28–8) and PD-1 expression. ***, p < 0.001.

Back to article page